Investments
73Portfolio Exits
8Funds
5Partners & Customers
1About Sinopharm Capital
Sinopharm Capital, under Sinopharm Group, is a professional PE company specialized in medical and healthcare industry. The funds are managed by a team of Sinopharm Group senior management team members, investment bank experts and professional investors, who has profound understanding about development and operation of Chinese medical and healthcare industry and rich knowledge of capital operation. We have the capability to efficiently integrate both internal and external Sinopharm Group resources, industry resources and capital strengths.
Want to inform investors similar to Sinopharm Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Sinopharm Capital News
Mar 31, 2022
All Rights Reserved. Disclaimer: The views, opinions, forecasts, and statements made by our hosts and guests are the personal views of those respective individuals and may or may not be either endorsed or accepted by China Money Network Limited or the companies with which these individuals are employed. Posting....
Sinopharm Capital Investments
73 Investments
Sinopharm Capital has made 73 investments. Their latest investment was in Leio Scientific as part of their Seed - III on September 9, 2023.
Sinopharm Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
9/8/2023 | Seed - III | Leio Scientific | Yes | 3 | ||
8/1/2022 | Series B | Origiencell | $120M | Yes | Boquan Investment, C&D Emerging Investment, E-Town International Investment & Development, Qiming Venture Partners, Quan Capital, Sinopharm Capital, Suzhou Fund, and Undisclosed Investors | 1 |
6/29/2022 | Series A | AstraBio | $14.93M | Yes | BioTrack Capital, Puhua Capital, Sinopharm Capital, and Undisclosed Investors | 3 |
3/31/2022 | Seed VC - III | |||||
3/31/2022 | Seed VC |
Date | 9/8/2023 | 8/1/2022 | 6/29/2022 | 3/31/2022 | 3/31/2022 |
|---|---|---|---|---|---|
Round | Seed - III | Series B | Series A | Seed VC - III | Seed VC |
Company | Leio Scientific | Origiencell | AstraBio | ||
Amount | $120M | $14.93M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | Boquan Investment, C&D Emerging Investment, E-Town International Investment & Development, Qiming Venture Partners, Quan Capital, Sinopharm Capital, Suzhou Fund, and Undisclosed Investors | BioTrack Capital, Puhua Capital, Sinopharm Capital, and Undisclosed Investors | |||
Sources | 3 | 1 | 3 |
Sinopharm Capital Portfolio Exits
8 Portfolio Exits
Sinopharm Capital has 8 portfolio exits. Their latest portfolio exit was InventisBio on July 25, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
7/25/2022 | IPO | Public | 1 | ||
Date | 7/25/2022 | ||||
|---|---|---|---|---|---|
Exit | IPO | ||||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 1 |
Sinopharm Capital Fund History
5 Fund Histories
Sinopharm Capital has 5 funds, including Sino-Singapore Healthcare Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
6/21/2019 | Sino-Singapore Healthcare Fund | $150M | 1 | ||
Sinopharm Medical Device Equity Investment Fund | |||||
Shanghai Sinopharm Equity Investment Fund Partners | |||||
Sinopharm Healthcare Fund LP | |||||
Shanghai Sinopharm Medical Equiptments Equity Investment Fund LP |
Closing Date | 6/21/2019 | ||||
|---|---|---|---|---|---|
Fund | Sino-Singapore Healthcare Fund | Sinopharm Medical Device Equity Investment Fund | Shanghai Sinopharm Equity Investment Fund Partners | Sinopharm Healthcare Fund LP | Shanghai Sinopharm Medical Equiptments Equity Investment Fund LP |
Fund Type | |||||
Status | |||||
Amount | $150M | ||||
Sources | 1 |
Sinopharm Capital Partners & Customers
1 Partners and customers
Sinopharm Capital has 1 strategic partners and customers. Sinopharm Capital recently partnered with Novena Global Lifecare on June 6, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
6/24/2019 | Partner | Singapore | Mr. Bao Yi , Founder and Chairman of Cedarlake Capital , said : `` We are delighted to partner Sinopharm Capital in its strategic investment in the Sino-Singapore Healthcare Fund and Novena Global Lifecare as we believe there is an immense opportunity to create win-win cross-border opportunities . | 1 |
Date | 6/24/2019 |
|---|---|
Type | Partner |
Business Partner | |
Country | Singapore |
News Snippet | Mr. Bao Yi , Founder and Chairman of Cedarlake Capital , said : `` We are delighted to partner Sinopharm Capital in its strategic investment in the Sino-Singapore Healthcare Fund and Novena Global Lifecare as we believe there is an immense opportunity to create win-win cross-border opportunities . |
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
